Genetic Phenotypes of Alzheimer’s Disease: Mechanisms and Potential Therapy

Abe-Dohmae S, Yokoyama S (2021) ABCA7 links sterol metabolism to the host defense system: molecular background for potential management measure of Alzheimer’s disease. Gene 768:145316. https://doi.org/10.1016/j.gene.2020.145316

Aikawa T, Holm ML, Kanekiyo T (2018) ABCA7 and pathogenic pathways of Alzheimer’s Disease. Brain Sci 8:27. https://doi.org/10.3390/brainsci8020027

Aikawa T, Ren Y, Yamazaki Y et al (2019) ABCA7 haplodeficiency disturbs microglial immune responses in the mouse brain. Proc Natl Acad Sci U S A 116:23790–23796. https://doi.org/10.1073/pnas.1908529116

Aikawa T, Ren Y, Holm ML et al (2021) ABCA7 Regulates brain fatty acid metabolism during LPS-induced acute inflammation. Front Neurosci 15:647974. https://doi.org/10.3389/fnins.2021.647974

Algahtani H, Shirah B, Alshareef A et al (2020) A novel variant c.3706C > T p. (Avg 1236Cys) in the ABCA7 gene in a Saudi patient with susceptibility to Alzheimer’s disease 9. Intractable Rare Dis Res 9:151–155. https://doi.org/10.5582/irdr.2020.03033

Almqvist E, Lake S, Axelman K et al (1993) Screening of amyloid precursor protein gene mutation (APP 717 Val–>Ile) in Swedish families with Alzheimer’s disease. J Neural Transm Park Dis Dement Sect 6:151–156. https://doi.org/10.1007/BF02261009

Andrew RJ, Kellett KA, Thinakaran G et al (2016) A greek tragedy: the growing complexity of Alzheimer amyloid precursor protein proteolysis. J Biol Chem 291:19235–19244. https://doi.org/10.1074/jbc.R116.746032

Arber C, Lovejoy C, Harris L et al (2021) Familial Alzheimer’s disease mutations in PSEN1 lead to premature human stem cell neurogenesis. Cell Rep 34:108615. https://doi.org/10.1016/j.celrep.2020.108615

Armstrong RA (2014) Factors determining disease duration in Alzheimer’s disease: a postmortem study of 103 cases using the Kaplan–Meier estimator and cox regression. Biomed Res Int 2014:623487. https://doi.org/10.1155/2014/623487

Barthelson K, Pederson SM, Newman M et al (2020) Brain transcriptome analysis reveals subtle effects on mitochondrial function and iron homeostasis of mutations in the SORL1 gene implicated in early onset familial Alzheimer’s disease. Mol Brain 13:142. https://doi.org/10.1186/s13041-020-00681-7

Bateman RJ, Aisen PS, De Strooper B et al (2011) Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther 3:1. https://doi.org/10.1186/alzrt59

Bateman RJ, Xiong C, Benzinger TL et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367:795–804. https://doi.org/10.1056/NEJMoa1202753

Beecham GW, Martin ER, Li YJ et al (2009) Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet 84:35–43. https://doi.org/10.1016/j.ajhg.2008.12.008

Bellenguez C, Kucukali F, Jansen IE et al (2022) New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet 54:412–436. https://doi.org/10.1038/s41588-022-01024-z

Belloy ME, Napolioni V, Greicius MD (2019) A Quarter century of APOE and Alzheimer’s disease: progress to date and the path forward. Neuron 101:820–838. https://doi.org/10.1016/j.neuron.2019.01.056

Bennett RE, Robbins AB, Hu M et al (2018) Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer’s disease. Proc Natl Acad Sci U S A 115:E1289–E1298. https://doi.org/10.1073/pnas.1710329115

Bertram L, McQueen MB, Mullin K et al (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39:17–23. https://doi.org/10.1038/ng1934

Bigio EH, Hynan LS, Sontag E et al (2002) Synapse loss is greater in presenile than senile onset Alzheimer disease: implications for the cognitive reserve hypothesis. Neuropathol Appl Neurobiol 28:218–227. https://doi.org/10.1046/j.1365-2990.2002.00385.x

Blurton-Jones M, Kitazawa M, Martinez-Coria H et al (2009) Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A 106:13594–13599. https://doi.org/10.1073/pnas.0901402106

Blurton-Jones M, Spencer B, Michael S et al (2014) Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. Stem Cell Res Ther 5:46. https://doi.org/10.1186/scrt440

Bocharov EV, Nadezhdin KD, Urban AS et al (2019) Familial L723P mutation can shift the distribution between the alternative APP transmembrane domain cleavage cascades by local unfolding of the epsilon-cleavage site suggesting a straightforward mechanism of Alzheimer’s disease pathogenesis. ACS Chem Biol 14:1573–1582. https://doi.org/10.1021/acschembio.9b00309

Bossaerts L, Hens E, Hanseeuw B et al (2021) Premature termination codon mutations in ABCA7 contribute to Alzheimer’s disease risk in Belgian patients. Neurobiol Aging 106:307.e1–e7. https://doi.org/10.1016/j.neurobiolaging.2021.04.023

Bossaerts L, Hendrickx Van de Craen E, Cacace R et al (2022) Rare missense mutations in ABCA7 might increase Alzheimer’s disease risk by plasma membrane exclusion. Acta Neuropathol Commun 10:43. https://doi.org/10.1186/s40478-022-01346-3

Cacace R, Sleegers K, Van Broeckhoven C (2016) Molecular genetics of early-onset Alzheimer’s disease revisited. Alzheimers Dement 12:733–748. https://doi.org/10.1016/j.jalz.2016.01.012

Cairns NJ, Perrin RJ, Franklin EE et al (2015) Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer disease neuroimaging Initiative (ADNI) and the dominantly Inherited Alzheimer network (DIAN). Neuropathology 35:390–400. https://doi.org/10.1111/neup.12205

Campion D, Charbonnier C, Nicolas G (2019) SORL1 genetic variants and Alzheimer disease risk: a literature review and meta-analysis of sequencing data. Acta Neuropathol 138:173–186. https://doi.org/10.1007/s00401-019-01991-4

Carmona S, Zahs K, Wu E et al (2018) The role of TREM2 in Alzheimer’s disease and other neurodegenerative disorders. Lancet Neurol 17:721–730. https://doi.org/10.1016/S1474-4422(18)30232-1

Carrasquillo MM, Zou F, Pankratz VS et al (2009) Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer’s disease. Nat Genet 41:192–198. https://doi.org/10.1038/ng.305

Chen YG (2018) Research progress in the pathogenesis of Alzheimer’s disease. Chin Med J (Engl) 131:1618–1624. https://doi.org/10.4103/0366-6999.235112

Chhatwal JP, Schultz SA, McDade E et al (2022) Variant-dependent heterogeneity in amyloid beta burden in autosomal dominant Alzheimer’s disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurol 21:140–152. https://doi.org/10.1016/S1474-4422(21)00375-6

Cho YY, Kwon OH, Park MK et al (2019) Elevated cellular cholesterol in Familial Alzheimer’s presenilin 1 mutation is associated with lipid raft localization of beta-amyloid precursor protein. PLoS ONE 14:e0210535. https://doi.org/10.1371/journal.pone.0210535

Coon KD, Myers AJ, Craig DW et al (2007) A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer’s disease. J Clin Psychiatry 68:613–618. https://doi.org/10.4088/jcp.v68n0419

Corder EH, Saunders AM, Strittmatter WJ et al (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261:921–923. https://doi.org/10.1126/science.8346443

Cuccaro ML, Carney RM, Zhang Y et al (2016) SORL1 mutations in early- and late-onset Alzheimer disease. Neurol Genet 2:e116. https://doi.org/10.1212/NXG.0000000000000116

Di Marco LY, Venneri A, Farkas E et al (2015) Vascular dysfunction in the pathogenesis of Alzheimer’s disease–A review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol Dis 82:593–606. https://doi.org/10.1016/j.nbd.2015.08.014

Dos Santos RB, Kanekiyo T, Singh J (2019) ApoE-2 brain-targeted gene therapy through transferrin and penetratin tagged liposomal nanoparticles. Pharm Res 36:161. https://doi.org/10.1007/s11095-019-2691-7

Erickson MA, Niehoff ML, Farr SA et al (2012) Peripheral administration of antisense oligonucleotides targeting the amyloid-beta protein precursor reverses AbetaPP and LRP-1 overexpression in the aged SAMP8 mouse brain. J Alzheimers Dis 28:951–960. https://doi.org/10.3233/JAD-2011-111517

Evangelisti E, Wright D, Zampagni M et al (2013) Lipid rafts mediate amyloid-induced calcium dyshomeostasis and oxidative stress in Alzheimer’s disease. Curr Alzheimer Res 10:143–153. https://doi.org/10.2174/1567205011310020004

Fedeli C, Filadi R, Rossi A et al (2019) PSEN2 (presenilin 2) mutants linked to familial Alzheimer disease impair autophagy by altering Ca(2+) homeostasis. Autophagy 15:2044–2062. https://doi.org/10.1080/15548627.2019.1596489

Fernandez MA, Klutkowski JA, Freret T et al (2014) Alzheimer presenilin-1 mutations dramatically reduce trimming of long amyloid beta-peptides (Abeta) by gamma-secretase to increase 42-to-40-residue Abeta. J Biol Chem 289:31043–31052. https://doi.org/10.1074/jbc.M114.581165

Filipello F, Morini R, Corradini I et al (2018) The Microglial innate immune receptor TREM2 is required for synapse elimination and normal brain connectivity. Immunity 48:979–991. https://doi.org/10.1016/j.immuni.2018.04.016

Fischer W, Wictorin K, Bjorklund A et al (1987) Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 329:65–68. https://doi.org/10.1038/329065a0

Forero DA, Casadesus G, Perry G et al (2006) Synaptic dysfunction and oxidative stress in Alzheimer’s disease: emerging mechanisms. J Cell Mol Med 10:796–805. https://doi.org/10.1111/j.1582-4934.2006.tb00439.x

Frisoni GB, Altomare D, Thal DR et al (2022) The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat Rev Neurosci 23:53–66. https://doi.org/10.1038/s41583-021-00533-w

Fung S, Smith CL, Prater KE et al (2020) Early-onset familial Alzheimer disease variant PSEN2 N141I heterozygosity is associated with altered microglia phenotype. J Alzheimers Dis 77:675–688. https://doi.org/10.3233/JAD-200492

Galla L, Redolfi N, Pozzan T et al (2020) Intracellular calcium dysregulation by the Alzheimer’s disease-linked protein presenilin 2. Int J Mol Sci 21:770. https://doi.org/10.3390/ijms21030770

Genin E, Hannequin D, Wallon D et al (2011) APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 16:903–907. https://doi.org/10.1038/mp.2011.52

Goate A, Chartier-Harlin MC, Mullan M et al (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349:704–706. https://doi.org/10.1038/349704a0

Goldman JS, Hahn SE, Catania JW et al (2011) Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American college of medical genetics and the national society of genetic counselors. Genet Med 13:597–605. https://doi.org/10.1097/GIM.0b013e31821d69b8

Gomez-Isla T, Growdon WB, McNamara MJ et al (1999) The impact of different presenilin 1 andpresenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer’s disease brain: evidence for other phenotype-modifying factors. Brain 122(Pt 9):1709–1719. https://doi.org/10.1093/brain/122.9.1709

Gomez-Tortosa E, Ruggiero M, Sainz MJ et al (2018) SORL1 variants in familial Alzheimer’s disease. J Alzheimers Dis 61:1275–1281. https://doi.org/10.3233/JAD-170590

Gotz J, Ittner LM, Schonrock N et al (2008) An update on the toxicity of Abeta in Alzheimer’s disease. Neuropsychiatr Dis Treat 4:1033–1042. https://doi.org/10.2147/ndt.s3016

Greotti E, Capitanio P, Wong A et al (2019) Familial Alzheimer’s disease-linked presenilin mutants and intracellular Ca(2+) handling: A single-organelle, FRET-based analysis. Cell Calcium 79:44–56. https://doi.org/10.1016/j.ceca.2019.02.005

Guerreiro R, Wojtas A, Bras J et al (2013) TREM2 variants in Alzheimer’s disease. N Engl J Med 368:117–127. https://doi.org/10.1056/NEJMoa1211851

Guo Q, Sebastian L, Sopher BL et al (1999) Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc Natl Acad Sci U S A 96:4125–4130. https://doi.org/10.1073/pnas.96.7.4125

Guo Y, Wang Q, Chen S et al (2021) Functions of amyloid precursor protein in metabolic diseases. Metabolism 115:154454. https://doi.org/10.1016/j.metabol.2020.154454

Hartl D, Nebrich G, Klein O et al (2016) SORLA regulates calpain-dependent degradation of synapsin. Alzheimers Dement 12:952–963. https://doi.org/10.1016/j.jalz.2016.02.008

Hinrich AJ, Jodelka FM, Chang JL et al (2016) Therapeutic correction of ApoER2 splicing in Alzheimer’s disease mice using antisense oligonucleotides. EMBO Mol Med 8:328–345. https://doi.org/10.15252/emmm.201505846

Huang W, Qiu C, von Strauss E et al (2004) APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study. Arch Neurol 61:1930–1934. https://doi.org/10.1001/archneur.61.12.1930

Hung C, Tuck E, Stubbs V et al (2021) SORL1 deficiency in human excitatory neurons causes APP-dependent defects in the endolysosome-autophagy network. Cell Rep 35:109259. https://doi.org/10.1016/j.celrep.2021.109259

Huynh TV, Liao F, Francis CM et al (2017) Age-dependent effects of apoe reduction using antisense oligonucleotides in a model of beta-amyloidosis. Neuron 96:1013–1023. https://doi.org/10.1016/j.neuron.2017.11.014

Iqbal J, Suarez MD, Yadav PK et al (2022) ATP-binding cassette protein ABCA7 deficiency impairs sphingomyelin synthesis, cognitive discrimination, and synaptic plasticity in the entorhinal cortex. J Biol Chem 298:102411. https://doi.org/10.1016/j.jbc.2022.102411

Jack CR Jr (2022) Advances in Alzheimer’s disease research over the past two decades. Lancet Neurol 21:866–869. https://doi.org/10.1016/S1474-4422(22)00298-8

Jackson RJ, Meltzer JC, Nguyen H et al (2022) APOE4 derived from astrocytes leads to blood-brain barrier impairment. Brain 145:3582–3593. https://doi.org/10.1093/brain/awab478

Janicki SM, Stabler SM, Monteiro MJ (2000) Familial Alzheimer’s disease presenilin-1 mutants potentiate cell cycle arrest. Neurobiol Aging 21:829–836. https://doi.org/10.1016/s0197-4580(00)00222-0

Jayadev S, Leverenz JB, Steinbart E et al (2010) Alzheimer’s disease phenotypes and genotypes associated with mutations in presenilin 2. Brain 133:1143–1154. https://doi.org/10.1093/brain/awq033

Jayadev S, Case A, Alajajian B et al (2013) Presenilin 2 influences miR146 level and activity in microglia. J Neurochem 127:592–599. https://doi.org/10.1111/jnc.12400

Jia J, Xu E, Shao Y et al (2005) One novel presenilin-1 gene mutation in a Chinese pedigree of familial Alzheimer’s disease. J Alzheimers Dis 7:119–124. https://doi.org/10.3233/jad-2005-7204

Jia L, Du Y, Chu L et al (2020a) Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health 5:e661–e671. https://doi.org/10.1016/S2468-2667(20)30185-7

Jia L, Fu Y, Shen L et al (2020b) PSEN1, PSEN2, and APP mutations in 404 Chinese pedigrees with familial Alzheimer’s disease. Alzheimers Dement 16:178–191. https://doi.org/10.1002/alz.12005

Jia L, Xu H, Chen S et al (2020c) The APOE epsilon4 exerts differential effects on familial and other subtypes of Alzheimer’s disease. Alzheimers Dement 16:1613–1623. https://doi.org/10.1002/alz.12153

Jonsson T, Stefansson H, Steinberg S et al (2013) Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med 368:107–116. https://doi.org/10.1056/NEJMoa1211103

Karsak M, Glebov K, Scheffold M et al (2020) A rare heterozygous TREM2 coding variant identified in familial clustering of dementia affects an intrinsically disordered protein region and function of TREM2. Hum Mutat 41:169–181. https://doi.org/10.1002/humu.23904

Katsouri L, Lim YM, Blondrath K et al (2016) PPARgamma-coactivator-1alpha gene transfer reduces neuronal loss and amyloid-beta generation by reducing beta-secretase in an Alzheimer’s disease model. Proc Natl Acad Sci U S A 113:12292–12297. https://doi.org/10.1073/pnas.1606171113

Kaur D, Sharma V, Deshmukh R (2019) Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer’s disease. Inflammopharmacology 27:663–677. https://doi.org/10.1007/s10787-019-00580-x

Khan S, Barve KH, Kumar MS (2020) Recent Advancements in pathogenesis, diagnostics and treatment of Alzheimer’s disease. Curr Neuropharmacol 18:1106–1125. https://doi.org/10.2174/1570159X18666200528142429

Kiyota T, Ingraham KL, Jacobsen MT et al (2011) FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer’s disease and has therapeutic implications for neurocognitive disorders. Proc Natl Acad Sci U S A 108:E1339–1348. https://doi.org/10.1073/pnas.1102349108

Kodamullil AT, Iyappan A, Karki R et al (2017) Of mice and men: comparative analysis of neuro-inflammatory mechanisms in human and mouse using cause-and-effect models. J Alzheimers Dis 59:1045–1055. https://doi.org/10.3233/JAD-170255

Korvatska O, Leverenz JB, Jayadev S et al (2015) R47H variant of TREM2 associated with Alzheimer Disease in a large late-onset family: clinical, genetic, and neuropathological study. JAMA Neurol 72:920–927. https://doi.org/10.1001/jamaneurol.2015.0979

Korvatska O, Kiianitsa K, Ratushny A et al (2020) Triggering receptor expressed on myeloid Cell 2 R47H exacerbates immune response in Alzheimer’s disease Brain. Front Immunol 11:559342. https://doi.org/10.3389/fimmu.2020.559342

Koutsodendris N, Nelson MR, Rao A et al (2022) Apolipoprotein E and Alzheimer’s disease: findings, hypotheses, and potential mechanisms. Annu Rev Pathol 17:73–99. https://doi.org/10.1146/annurev-pathmechdis-030421-112756

Kunkle BW, Carney RM, Kohli MA et al (2017) Targeted sequencing of ABCA7 identifies splicing, stop-gain and intronic risk variants for Alzheimer disease. Neurosci Lett 649:124–129. https://doi.org/10.1016/j.neulet.2017.04.014

Lee J, Chan SL, Mattson MP (2002) Adverse effect of a presenilin-1 mutation in microglia results in enhanced nitric oxide and inflammatory cytokine responses to immune challenge in the brain. Neuromolecular Med 2:29–45. https://doi.org/10.1385/NMM:2:1:29

Lee HJ, Lim IJ, Park SW et al (2012) Human neural stem cells genetically modified to express human nerve growth factor (NGF) gene restore cognition in the mouse with ibotenic acid-induced cognitive dysfunction. Cell Transplant 21:2487–2496. https://doi.org/10.3727/096368912X638964

Lee SH, Meilandt WJ, Xie L et al (2021) Trem2 restrains the enhancement of tau accumulation and neurodegeneration by beta-amyloid pathology. Neuron 109:1283–1301. https://doi.org/10.1016/j.neuron.2021.02.010

Levy-Lahad E, Wasco W, Poorkaj P et al (1995) Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 269:973–977. https://doi.org/10.1126/science.7638622

Li YM, Xu M, Lai MT et al (2000) Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405:689–694. https://doi.org/10.1038/35015085

Li Y, Grupe A, Rowland C et al (2006) DAPK1 variants are associated with Alzheimer’s disease and allele-specific expression. Hum Mol Genet 15:2560–2568. https://doi.org/10.1093/hmg/ddl178

Li Q, Liu Y, Sun M (2017) Autophagy and Alzheimer’s disease. Cell Mol Neurobiol 37:377–388. https://doi.org/10.1007/s10571-016-0386-8

Li Y, Laws SM, Miles LA et al (2021) Genomics of Alzheimer’s disease implicates the innate and adaptive immune systems. Cell Mol Life Sci 78:7397–7426. https://doi.org/10.1007/s00018-021-03986-5

Lista S, O’Bryant SE, Blennow K et al (2015) Biomarkers in sporadic and familial Alzheimer’s disease. J Alzheimers Dis 47:291–317. https://doi.org/10.3233/JAD-143006

Liu Y, Wang DA (2015) Viral vector-mediated transgenic cell therapy in regenerative medicine: safety of the process. Expert Opin Biol Ther 15:559–567. https://doi.org/10.1517/14712598.2015.995086

Liu CC, Liu CC, Kanekiyo T et al (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9:106–118. https://doi.org/10.1038/nrneurol.2012.263

Livingston G, Huntley J, Sommerlad A et al (2020) Dementia prevention, intervention, and care: 2020 report of the lancet commission. Lancet 396:413–446. https://doi.org/10.1016/S0140-6736(20)30367-6

Long JM, Holtzman DM (2019) Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179:312–339. https://doi.org/10.1016/j.cell.2019.09.001

Lopera F, Ardilla A, Martinez A et al (1997) Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 277:793–799

Louwersheimer E, Cohn-Hokke PE, Pijnenburg YA et al (2017) Rare genetic variant in sorl1 may increase penetrance of Alzheimer’s disease in a family with several generations of APOE-varepsilon4 homozygosity. J Alzheimers Dis 56:63–74. https://doi.org/10.3233/JAD-160091

Loy CT, Schofield PR, Turner AM et al (2014) Genetics of dementia. Lancet 383:828–840. https://doi.org/10.1016/S0140-6736(13)60630-3

Lu J, Cao Q, Wang C et al (2019) Structure-based peptide inhibitor design of amyloid-β aggregation. Front Mol Neurosci 12:54. https://doi.org/10.3389/fnmol.2019.00054

Maarouf CL, Daugs ID, Spina S et al (2008) Histopathological and molecular heterogeneity among individuals with dementia associated with Presenilin mutations. Mol Neurodegener 3:20. https://doi.org/10.1186/1750-1326-3-20

Manczak M, Kandimalla R, Yin X et al (2018) Hippocampal mutant APP and amyloid beta-induced cognitive decline, dendritic spine loss, defective autophagy, mitophagy and mitochondrial abnormalities in a mouse model of Alzheimer’s disease. Hum Mol Genet 27:1332–1342. https://doi.org/10.1093/hmg/ddy042

Manoharan S, Guillemin GJ, Abiramasundari RS et al (2016) The role of reactive oxygen species in the pathogenesis of Alzheimer’s disease, parkinson’s disease, and huntington’s disease: a mini review. Oxid Med Cell Long 2016:1–15. https://doi.org/10.1155/2016/8590578

Martens YA, Zhao N, Liu CC et al (2022) ApoE Cascade Hypothesis in the pathogenesis of Alzheimer’s disease and related dementias. Neuron 110:1304–1317. https://doi.org/10.1016/j.neuron.2022.03.004

Martinez M, Campion D, Brice A et al (1998) Apolipoprotein E epsilon4 allele and familial aggregation of Alzheimer disease. Arch Neurol 55:810–816. https://doi.org/10.1001/archneur.55.6.810

Mattson MP (2002) Oxidative stress, perturbed calcium homeostasis, and immune dysfunction in Alzheimer’s disease. J Neurovirol 8:539–550. https://doi.org/10.1080/13550280290100978

May P, Pichler S, Hartl D et al (2018) Rare ABCA7 variants in 2 German families with Alzheimer disease. Neurol Genet 4:e224. https://doi.org/10.1212/NXG.0000000000000224

Mendell JR, Al-Zaidy SA, Rodino-Klapac LR et al (2021) Current clinical applications of in vivo gene therapy with AAVs. Mol Ther 29:464–488. https://doi.org/10.1016/j.ymthe.2020.12.007

Meraz-Rios MA, Franco-Bocanegra D, Toral Rios D et al (2014) Early onset alzheimer’s disease and oxidative stress. Oxid Med Cell Longev 2014:375968. https://doi.org/10.1155/2014/375968

Migliore L, Coppede F (2022) Gene-environment interactions in Alzheimer disease: the emerging role of epigenetics. Nat Rev Neurol 18:643–660. https://doi.org/10.1038/s41582-022-00714-w

Mishra R, Phan T, Kumar P et al (2022a) Augmenting neurogenesis rescues memory impairments in Alzheimer’s disease by restoring the memory-storing neurons. J Exp Med 219:e20220391. https://doi.org/10.1084/jem.20220391

Mishra S, Knupp A, Szabo MP et al (2022b) The Alzheimer’s gene SORL1 is a regulator of endosomal traffic and recycling in human neurons. Cell Mol Life Sci 79:162. https://doi.org/10.1007/s00018-022-04182-9

Moloudizargari M, Asghari MH, Ghobadi E et al (2017) Autophagy, its mechanisms and regulation: Implications in neurodegenerative diseases. Ageing Res Rev 40:64–74. https://doi.org/10.1016/j.arr.2017.09.005

Muchnik C, Olivar N, Dalmasso MC et al (2015) Identification of PSEN2 mutation p.N141I in Argentine pedigrees with early-onset familial Alzheimer’s disease. Neurobiol Aging 36:2674–2677. https://doi.org/10.1016/j.neurobiolaging.2015.06.011

Mullan M, Crawford F, Axelman K et al (1992) A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1:345–347. https://doi.org/10.1038/ng0892-345

Naaldijk Y, Jager C, Fabian C et al (2017) Effect of systemic transplantation of bone marrow-derived mesenchymal stem cells on neuropathology markers in APP/PS1 Alzheimer mice. Neuropathol Appl Neurobiol 43:299–314. https://doi.org/10.1111/nan.12319

Naj AC, Schellenberg GD, Alzheimer’s Disease Genetics C (2017) Genomic variants, genes, and pathways of Alzheimer’s disease: An overview. Am J Med Genet B Neuropsychiatr Genet 174:5–26. https://doi.org/10.1002/ajmg.b.32499

Neuner SM, Tcw J, Goate AM (2020) Genetic architecture of Alzheimer’s disease. Neurobiol Dis 143:104976. https://doi.org/10.1016/j.nbd.2020.104976

Nguyen HN, Son DJ, Lee JW et al (2006) Mutant presenilin 2 causes abnormality in the brain lipid profile in the development of Alzheimer’s disease. Arch Pharm Res 29:884–889. https://doi.org/10.1007/BF02973910

Oxtoby NP, Young AL, Cash DM et al (2018) Data-driven models of dominantly-inherited Alzheimer’s disease progression. Brain 141:1529–1544. https://doi.org/10.1093/brain/awy050

Pang Y, Li T, Wang Q et al (2021) A Rare Variation in the 3’ untranslated region of the presenilin 2 gene is linked to Alzheimer’s disease. Mol Neurobiol 58:4337–4347. https://doi.org/10.1007/s12035-021-02429-3

Pang K, Jiang R, Zhang W et al (2022) An App knock-in rat model for Alzheimer’s disease exhibiting Abeta and tau pathologies, neuronal death and cognitive impairments. Cell Res 32:157–175. https://doi.org/10.1038/s41422-021-00582-x

Parambi DGT, Alharbi KS, Kumar R et al (2022) Gene therapy approach with an emphasis on growth factors: theoretical and clinical outcomes in neurodegenerative diseases. Mol Neurobiol 59:191–233. https://doi.org/10.1007/s12035-021-02555-y

Paroni G, Bisceglia P, Seripa D (2019) Understanding the amyloid hypothesis in Alzheimer’s disease. J Alzheimers Dis 68:493–510. https://doi.org/10.3233/JAD-180802

Perdigao C, Barata MA, Araujo MN et al (2020) Intracellular trafficking mechanisms of synaptic dysfunction in Alzheimer’s disease. Front Cell Neurosci 14:72. https://doi.org/10.3389/fncel.2020.00072

Pericak-Vance MA, Bebout JL, Gaskell PC Jr et al (1991) Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. Am J Hum Genet 48:1034–1050

Piaceri I, Nacmias B, Sorbi S (2013) Genetics of familial and sporadic Alzheimer’s disease. Front Biosci (elite Ed) 5:167–177. https://doi.org/10.2741/e605

Pizzo P, Basso E, Filadi R et al (2020) Presenilin-2 and calcium handling: molecules, organelles, cells and brain networks. Cells 9:2166. https://doi.org/10.3390/cells9102166

Poirier J, Davignon J, Bouthillier D et al (1993) Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet 342:697–699. https://doi.org/10.1016/0140-6736(93)91705-q

Pottier C, Hannequin D, Coutant S et al (2012) High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry 17:875–879. https://doi.org/10.1038/mp.2012.15

Pratt KG, Zimmerman EC, Cook DG et al (2011) Presenilin 1 regulates homeostatic synaptic scaling through Akt signaling. Nat Neurosci 14:1112–1114. https://doi.org/10.1038/nn.2893

Qin W, Li W, Wang Q et al (2021) Race-related association between APOE Genotype and Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis 83:897–906. https://doi.org/10.3233/JAD-210549

Quan M, Zhao T, Tang Y et al (2020) Effects of gene mutation and disease progression on representative neural circuits in familial Alzheimer’s disease. Alzheimers Res Ther 12:14. https://doi.org/10.1186/s13195-019-0572-2

Quiroz YT, Zetterberg H, Reiman EM et al (2020) Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer’s disease kindred: a cross-sectional and longitudinal cohort study. Lancet Neurol 19:513–521. https://doi.org/10.1016/S1474-4422(20)30137-X

Rafii MS, Baumann TL, Bakay RA et al (2014) A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer’s disease. Alzheimers Dement 10:571–581. https://doi.org/10.1016/j.jalz.2013.09.004

Rafii MS, Tuszynski MH, Thomas RG et al (2018) Adeno-associated viral vector (Serotype 2)-nerve growth factor for patients with Alzheimer disease: a randomized clinical trial. JAMA Neurol 75:834–841. https://doi.org/10.1001/jamaneurol.2018.0233

Ramirez Aguilar L, Acosta-Uribe J, Giraldo MM et al (2019) Genetic origin of a large family with a novel PSEN1 mutation (Ile416Thr). Alzheimers Dement 15:709–719. https://doi.org/10.1016/j.jalz.2018.12.010

Ray WJ, Ashall F, Goate AM (1998) Molecular pathogenesis of sporadic and familial forms of Alzheimer’s disease. Mol Med Today 4:151–157. https://doi.org/10.1016/s1357-4310(98)01229-5

Reddy PH, Yin X, Manczak M et al (2018) Mutant APP and amyloid beta-induced defective autophagy, mitophagy, mitochondrial structural and functional changes and synaptic damage in hippocampal neurons from Alzheimer’s disease. Hum Mol Genet 27:2502–2516. https://doi.org/10.1093/hmg/ddy154

Reiman EM, Arboleda-Velasquez JF, Quiroz YT et al (2020) Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5000-person neuropathological study. Nat Commun 11:667. https://doi.org/10.1038/s41467-019-14279-8

Reyes-Dumeyer D, Faber K, Vardarajan B et al (2022) The national institute on aging late-onset Alzheimer’s disease family based study: a resource for genetic discovery. Alzheimers Dement 18:1889–1897. https://doi.org/10.1002/alz.12514

Rogaeva E, Meng Y, Lee JH et al (2007) The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 39:168–177. https://doi.org/10.1038/ng1943

Roher AE, Maarouf CL, Malek-Ahmadi M et al (2013) Subjects harboring presenilin familial Alzheimer’s disease mutations exhibit diverse white matter biochemistry alterations. Am J Neurodegener Dis 2:187–207

Roher AE, Maarouf CL, Kokjohn TA (2016) Familial presenilin mutations and sporadic Alzheimer’s disease pathology: is the assumption of biochemical equivalence justified? J Alzheimers Dis 50:645–658. https://doi.org/10.3233/JAD-150757

Rossi A, Galla L, Gomiero C et al (2021) Calcium signaling and mitochondrial function in presenilin 2 knock-out mice: looking for any loss-of-function phenotype related to Alzheimer’s disease. Cells 10:204. https://doi.org/10.3390/cells10020204

Rossini M, Garcia-Casas P, Filadi R et al (2021) Loosening ER-mitochondria coupling by the expression of the presenilin 2 loop domain. Cells 10:1968. https://doi.org/10.3390/cells10081968

Rothenberg C, Srinivasan D, Mah L et al (2010) Ubiquilin functions in autophagy and is degraded by chaperone-mediated autophagy. Hum Mol Genet 19:3219–3232. https://doi.org/10.1093/hmg/ddq231

Rovelet-Lecrux A, Legallic S, Wallon D et al (2012) A genome-wide study reveals rare CNVs exclusive to extreme phenotypes of Alzheimer disease. Eur J Hum Genet 20:613–617. https://doi.org/10.1038/ejhg.2011.225

Sawikr Y, Yarla NS, Peluso I et al (2017) Neuroinflammation in Alzheimer’s disease: the preventive and therapeutic potential of polyphenolic nutraceuticals. Adv Protein Chem Struct Biol 108:33–57. https://doi.org/10.1016/bs.apcsb.2017.02.001

Sayed FA, Kodama L, Fan L et al (2021) AD-linked R47H-TREM2 mutation induces disease-enhancing microglial states via AKT hyperactivation. Sci Transl Med 13:eabe3947. https://doi.org/10.1126/scitranslmed.abe3947

Scheltens P, De Strooper B, Kivipelto M et al (2021) Alzheimer’s disease. Lancet 397:1577–1590. https://doi.org/10.1016/S0140-6736(20)32205-4

Schuessel K, Frey C, Jourdan C et al (2006) Aging sensitizes toward ROS formation and lipid peroxidation in PS1M146L transgenic mice. Free Radic Biol Med 40:850–862. https://doi.org/10.1016/j.freeradbiomed.2005.10.041

Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766. https://doi.org/10.1152/physrev.2001.81.2.741

Serrano-Pozo A, Das S, Hyman BT (2021) APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol 20:68–80. https://doi.org/10.1016/S1474-4422(20)30412-9

Sherrington R, Rogaev EI, Liang Y et al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 375:754–760. https://doi.org/10.1038/375754a0

Strittmatter WJ, Saunders AM, Schmechel D et al (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90:1977–1981. https://doi.org/10.1073/pnas.90.5.1977

Suzuki N, Cheung TT, Cai XD et al (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264:1336–1340. https://doi.org/10.1126/science.8191290

Szaruga M, Munteanu B, Lismont S et al (2017) Alzheimer’s-causing mutations shift abeta length by destabilizing gamma-secretase-abetan interactions. Cell 170:443–456. https://doi.org/10.1016/j.cell.2017.07.004

Szaruga M, Munteanu B, Lismont S et al (2021) Alzheimer’s-causing mutations shift abeta length by destabilizing gamma-secretase-abetan interactions. Cell 184:2257–2258. https://doi.org/10.1016/j.cell.2021.03.058

Tackenberg C, Brandt R (2009) Divergent pathways mediate spine alterations and cell death induced by amyloid-beta, wild-type tau, and R406W tau. J Neurosci 29:14439–14450. https://doi.org/10.1523/JNEUROSCI.3590-09.2009

Tackenberg C, Kulic L, Nitsch RM (2020) Familial Alzheimer’s disease mutations at position 22 of the amyloid beta-peptide sequence differentially affect synaptic loss, tau phosphorylation and neuronal cell death in an ex vivo system. PLoS ONE 15:e0239584. https://doi.org/10.1371/journal.pone.0239584

Tanna T, Sachan V (2014) Mesenchymal stem cells: potential in treatment of neurodegenerative diseases. Curr Stem Cell Res Ther 9:513–521. https://doi.org/10.2174/1574888x09666140923101110

Tariot PN, Lopera F, Langbaum JB et al (2018) The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort. Alzheimers Dement (N Y) 4:150–160. https://doi.org/10.1016/j.trci.2018.02.002

Theuns J, Marjaux E, Vandenbulcke M et al (2006) Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment. Hum Mutat 27:888–896. https://doi.org/10.1002/humu.20402

Thonberg H, Chiang HH, Lilius L et al (2017) Identification and description of three families with familial Alzheimer disease that segregate variants in the SORL1 gene. Acta Neuropathol Commun 5:43. https://doi.org/10.1186/s40478-017-0441-9

Tian Y, Bassit B, Chau D et al (2010) An APP inhibitory domain containing the Flemish mutation residue modulates gamma-secretase activity for Abeta production. Nat Struct Mol Biol 17:151–158. https://doi.org/10.1038/nsmb.1743

Tiwari S, Atluri V, Kaushik A et al (2019) Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine 14:5541–5554. https://doi.org/10.2147/IJN.S200490

Tomiyama T, Shimada H (2020) APP Osaka mutation in familial Alzheimer’s disease-its discovery, phenotypes, and mechanism of recessive inheritance. Int J Mol Sci 21:1413. https://doi.org/10.3390/ijms21041413

Tönnies E, Trushina E (2017) Oxidative stress, synaptic dysfunction, and Alzheimer’s disease. J Alzheimers Dis 57:1105–1121. https://doi.org/10.3233/jad-161088

Tuszynski MH, Yang JH, Barba D et al (2015) Nerve growth factor gene therapy: activation of neuronal responses in Alzheimer disease. JAMA Neurol 72:1139–1147. https://doi.org/10.1001/jamaneurol.2015.1807

Ulland TK, Colonna M (2018) TREM2 - a key player in microglial biology and Alzheimer disease. Nat Rev Neurol 14:667–675. https://doi.org/10.1038/s41582-018-0072-1

Ulland TK, Song WM, Huang SC et al (2017) TREM2 maintains microglial metabolic fitness in Alzheimer’s disease. Cell 170:649–663. https://doi.org/10.1016/j.cell.2017.07.023

Van Cauwenberghe C, Van Broeckhoven C, Sleegers K (2016) The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med 18:421–430. https://doi.org/10.1038/gim.2015.117

Van Dooren T, Princen K, De Witte K et al (2014) Derailed intraneuronal signalling drives pathogenesis in sporadic and familial Alzheimer’s disease. Biomed Res Int 2014:167024. https://doi.org/10.1155/2014/167024

Van den Bossche T, Sleegers K, Cuyvers E et al (2016) Phenotypic characteristics of Alzheimer patients carrying an ABCA7 mutation. Neurology 86:2126–2133. https://doi.org/10.1212/WNL.0000000000002628

van Duijn CM, de Knijff P, Cruts M et al (1994) Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer’s disease. Nat Genet 7:74–78. https://doi.org/10.1038/ng0594-74

Vassar R, Bennett BD, Babu-Khan S et al (1999) Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735–741. https://doi.org/10.1126/science.286.5440.735

Velez JI, Lopera F, Sepulveda-Falla D et al (2016) APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease. Mol Psychiatry 21:916–924. https://doi.org/10.1038/mp.2015.177

Verheijen J, Sleegers K (2018) Understanding Alzheimer disease at the interface between genetics and transcriptomics. Trends Genet 34:434–447. https://doi.org/10.1016/j.tig.2018.02.007

Wang X, Wang W, Li L et al (2014) Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. Biochim Biophys Acta 1842:1240–1247. https://doi.org/10.1016/j.bbadis.2013.10.015

Wang W, Hou TT, Jia LF et al (2019) Toxic amyloid-beta oligomers induced self-replication in astrocytes triggering neuronal injury. EBioMedicine 42:174–187. https://doi.org/10.1016/j.ebiom.2019.03.049

Weston PSJ, Nicholas JM, Henley SMD et al (2018) Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer’s disease: a cross-sectional study. Lancet Neurol 17:123–132. https://doi.org/10.1016/S1474-4422(17)30434-9

Williams T, Borchelt DR, Chakrabarty P (2020) Therapeutic approaches targeting apolipoprotein E function in Alzheimer’s disease. Mol Neurodegener 15:8. https://doi.org/10.1186/s13024-020-0358-9

Wu S, Sasaki A, Yoshimoto R et al (2008) Neural stem cells improve learning and memory in rats with Alzheimer’s disease. Pathobiology 75:186–194. https://doi.org/10.1159/000124979

Wu CC, Lien CC, Hou WH et al (2016) Gain of BDNF function in engrafted neural stem cells promotes the therapeutic potential for Alzheimer’s disease. Sci Rep 6:27358. https://doi.org/10.1038/srep27358

Wu XL, Pina-Crespo J, Zhang YW et al (2017) Tau-mediated neurodegeneration and potential implications in diagnosis and treatment of Alzheimer’s disease. Chin Med J (Engl) 130:2978–2990. https://doi.org/10.4103/0366-6999.220313

Xia D, Lianoglou S, Sandmann T et al (2022) Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia. Mol Neurodegener 17:41. https://doi.org/10.1186/s13024-022-00547-7

Yang Y, Arseni D, Zhang W et al (2022) Cryo-EM structures of amyloid-beta 42 filaments from human brains. Science 375:167–172. https://doi.org/10.1126/science.abm7285

Zampese E, Fasolato C, Kipanyula MJ et al (2011) Presenilin 2 modulates endoplasmic reticulum (ER)-mitochondria interactions and Ca2+ cross-talk. Proc Natl Acad Sci U S A 108:2777–2782. https://doi.org/10.1073/pnas.1100735108

Zarea A, Charbonnier C, Rovelet-Lecrux A et al (2016) Seizures in dominantly inherited Alzheimer disease. Neurology 87:912–919. https://doi.org/10.1212/WNL.0000000000003048

Zhang S, Cai F, Wu Y et al (2020a) A presenilin-1 mutation causes Alzheimer disease without affecting Notch signaling. Mol Psychiatry 25:603–613. https://doi.org/10.1038/s41380-018-0101-x

Zhang W, Jiao B, Xiao T et al (2020b) Association of rare variants in neurodegenerative genes with familial Alzheimer’s disease. Ann Clin Transl Neurol 7:1985–1995. https://doi.org/10.1002/acn3.51197

Zhao Y, Wu X, Li X et al (2018) TREM2 Is a receptor for beta-amyloid that mediates microglial function. Neuron 97:1023–1031. https://doi.org/10.1016/j.neuron.2018.01.031

Zou L, Wang Z, Shen L et al (2007) Receptor tyrosine kinases positively regulate BACE activity and Amyloid-beta production through enhancing BACE internalization. Cell Res 17:389–401. https://doi.org/10.1038/cr.2007.5